The U.S. Senate held a July 25 hearing on the need for regulation of artificial intelligence (AI), which highlighted an interest in a single overarching agency that would direct any regulations promulgated for AI across the U.S. economy.
Medical device company Know Labs Inc. reported results from a new study showing that continued algorithm refinement combined with more high-quality data significantly increased the accuracy of its Body-Radio Frequency Identification, or Bio-RFID, sensor technology to measure and detect changes in blood glucose levels.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptitude Medical, Baxter, Caredx, Enzo, Epibone, Glucotrack, Illumina, Labcorp, Medigo, Metasight Diagnostics, Pacemate, Pillar Biosciences, Vantive.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Baropace, Imperative Care, Numares.
New hires and promotions in the med-tech industry, including: Allurion Technologies, Angiodynamics, Becton, Dickinson and Co., Braincheck, Inspire Medical Systems, Perosphere Technologies.
It only took a couple of billion-dollar transactions in the second quarter (Q2) of 2023 to push med-tech dealmaking values above all other recent years. Despite the surge in value, the volume of deals is level with other quarters.
Advocates are pressing the U.S. Congress to pass legislation to require more Medicare coverage of telehealth and telemedicine, but the Office of Inspector General (OIG) continues to report instances of fraud in this area. OIG reported July 24 that government attorneys had forced a guilty plea out of a telemedicine provider who has agreed to pay $44 million to deal with charges of fraud perpetrated over a period of three and a half years.
The U.K. government and the health care industry should focus more on behavioral-based approaches and preventative care in a bid to tackle health inequality, rising costs and an ageing population, Anton Derlyatka, CEO and co-founder of Sweatcoin Ltd., told BioWorld. Sweatcoin is a step-counting app that rewards users for their daily steps. The company has worked with the NHS for the last three years and is currently working on pilot programs to help tackle type 2 diabetes and cardiovascular diseases by incentivizing people to move.
RSS
